Future Eloxx Positions

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Ascidian Therapeutics

Ascribe Bioscience

Asher Biotherapeutics

Asimov

Eloxx Pharmaceuticals is developing ribosome targeted genetic therapies. Not all diseases are caused by mutations in the amino acid sequence of a protein. Around 10-12% of mutations are nonsense mutations that cause the synthesis of truncated proteins affecting more than 100,000 patients. Eloxx aims to correct these mutations with their TURBO-ZM technology and Eukaryotic Ribosomal Selective Glycosides Library that allows rapid synthesis of novel oral Ribosome Modulating Agents (RMAs).

RMAs are optimized compared to traditional macrolides to modulate protein synthesis, minimize antibiotic activity and be orally and chronically delivered. Eloxx has three initial programs focused on developing therapies for cystic fibrosis, junctional epidermolysis bullosa and APC mutant colorectal cancer.

<p>Eloxx Pharmaceuticals is developing ribosome targeted genetic therapies. Not all diseases are caused by mutations in the amino acid sequence of a protein. Around 10-12% of mutations are nonsense mutations that cause the synthesis of truncated proteins affecting more than 100,000 patients. Eloxx aims to correct these mutations with their TURBO-ZM technology and Eukaryotic Ribosomal Selective Glycosides Library that allows rapid synthesis of novel oral Ribosome Modulating Agents (RMAs).</p>
<p>RMAs are optimized compared to traditional macrolides to modulate protein synthesis, minimize antibiotic activity and be orally and chronically delivered. Eloxx has three initial programs focused on developing therapies for cystic fibrosis, junctional epidermolysis bullosa and APC mutant colorectal cancer.</p>


Eloxx Pharmaceuticals

Find a biotech startup job.